Open    Access



Pseudocirrhosis after the Use of Taxanes and Bevacizumab in Metastatic Breast Cancer: Case Reports



Author(s)

Gabriel Lima Lopes, Bruna Migliavacca Zucchetti, Juliana Florinda de Mendoça Rego, Daniela de Freitas and Ricardo José Marques

Full-Text PDF XML     563 Views

DOI:10.17265/2328-2150/2017.03.007

Currently, multiple lines of cytotoxic chemotherapy for treatment of metastatic breast cancer are available, and Taxanes, used as monotherapy or in combination with anti-angiogenic drugs, such as Bevacizumab, are one of the most used schemes in clinical practice. These drugs have different side effects and the liver is one of the most affected organs. The objective of this paper is to report three cases of metastatic breast cancer with positive expression of hormone receptors and without amplification of HER-2 protein that were treated with Taxane and Bevacizumab, developed pseudocirrosis probably caused by these drugs and died due to liver failure. It can be drawn from the study that liver failure, as a pseudocirrhosis evolution, is an unusual but lethal event that may occur during the treatment of metastatic breast cancer with Taxanes and Bevacizumab. This warns the importance of diagnostic suspicion of this pathology.

Breast cancer, Taxanes, Bevacizumab, Pseudocirrhosis, liver failure.

Lopes, G. L., et al. 2017. “Pseudocirrhosis after the Use of Taxanes and Bevacizumab in Metastatic Breast Cancer: Case Reports.” Journal of Pharmacy and Pharmacology 5 (3): 158-163.